Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Alteration in PI3K/mTOR, MAPK pathways and Her2 expression/amplification is more frequent in uterine serous carcinoma than ovarian serous carcinoma.

Journal of surgical oncology - 1 Aug 2015

Mahdi Haider, Xiu Joanne, Reddy Sandeep K, DeBernardo Robert

Abstract excerpt

OBJECTIVES: To compare the molecular profile of a large cohort of uterine papillary serous carcinoma (UPSC) and ovarian serous carcinoma (EOC-S). METHODS: 628 UPSC and 5335 EOC-S tumors were evaluated using a commercial multiplatform profiling service (CARIS Life Sciences, Phoenix, AZ). Specific testing performed included a combination of gene sequencing (Sanger, next generation sequencing), protein expression...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cystadenocarcinoma, Serous
Share to In Situ Hybridization, Fluorescence

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to MAP Kinase Signaling System

Share to Molecular Targeted Therapy

Share to Phosphatidylinositol 3-Kinases

Share to Receptor, ErbB-2

Share to TOR Serine-Threonine Kinases

Share to Uterine Neoplasms

Source

Identifiers

PMID: 26250968
DOI: 10.1002/jso.23993

Genes

BRCA1
BRCA2
CISH
CTNNB1
KRAS
PTEN

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Alteration in PI3K/mTOR, MAPK pathways and Her2 expression/amplification is more frequent in uterine serous carcinoma than ovarian serous carcinoma.PMID 26250968Read ↗

Identification of potential therapeutic targets by molecular profiling of 628 cases of uterine serous carcinoma.Semantic proximity Read ↗

Identification of molecular pathway aberrations in uterine serous carcinoma by genome-wide analyses.Semantic proximity Read ↗

Prevalence and Prognostic Relevance of Homologous Recombination Repair Gene Mutations in Uterine Serous Carcinoma.Semantic proximity Read ↗

Novel targeted therapies in uterine serous carcinoma, an aggressive variant of endometrial cancer.Semantic proximity Read ↗

Molecular analysis of endometrial serous carcinoma reveals distinct clinicopathologic and genomic subgroups.Semantic proximity Read ↗

Updates in therapy for uterine serous carcinomaSemantic proximity Read ↗

Morphologic correlates of molecular alterations in extrauterine Müllerian carcinomas.Semantic proximity Read ↗

Histopathologic features and molecular genetic landscape of HER2-amplified endometrial carcinomas.Semantic proximity Read ↗

Impact of BRCA mutations on outcomes among patients with serous endometrial cancer.Semantic proximity Read ↗

Germline mutations of the DNA repair pathways in uterine serous carcinoma.Semantic proximity Read ↗

Epithelial ovarian cancer: rationale for changing the one-fits-all standard treatment regimen to subtype-specific treatment.Semantic proximity Read ↗

Comprehensive Genomic Characterization in Ovarian Low-Grade and Chemosensitive and Chemoresistant High-Grade Serous Carcinomas.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.